Evotec SE (NASDAQ:EVO) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP grew its position in Evotec SE (NASDAQ:EVO - Free Report) by 29.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,634,434 shares of the company's stock after purchasing an additional 602,858 shares during the period. Wellington Management Group LLP owned approximately 0.74% of Evotec worth $9,616,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of EVO. Vanguard Personalized Indexing Management LLC acquired a new position in Evotec during the 2nd quarter worth approximately $87,000. Clear Harbor Asset Management LLC acquired a new position in shares of Evotec during the third quarter worth $104,000. Cetera Advisors LLC purchased a new position in shares of Evotec in the first quarter valued at $188,000. Mediolanum International Funds Ltd acquired a new stake in Evotec during the 3rd quarter valued at $512,000. Finally, DCF Advisers LLC increased its stake in Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock worth $552,000 after buying an additional 67,156 shares during the period. Hedge funds and other institutional investors own 5.81% of the company's stock.

Evotec Stock Up 4.0 %

EVO stock traded up $0.18 during mid-day trading on Monday, hitting $4.67. 194,360 shares of the company were exchanged, compared to its average volume of 132,743. The firm has a fifty day simple moving average of $4.22 and a 200 day simple moving average of $4.14. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. Evotec SE has a twelve month low of $2.85 and a twelve month high of $12.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on EVO shares. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of Evotec in a research report on Thursday, November 7th. Jefferies Financial Group downgraded Evotec from a "buy" rating to a "hold" rating and reduced their price target for the company from $8.70 to $3.80 in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $5.93.

Evotec Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.